Key Details
Price
$150.88Last Dividend
$0.75Annual Revenue
$9.25 BAnnual EPS
$7.49Annual ROE
13.75%Beta
0.25Events Calendar
Next earnings date:
Jan 30, 2025Recent quarterly earnings:
Oct 22, 2024Recent annual earnings:
Feb 01, 2024Next ex-dividend date:
Jan 14, 2025Recent ex-dividend date:
Oct 04, 2024Next split:
N/ARecent split:
June 21, 2005Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Quest Diagnostics (DGX) has a strong track record of surprising with its earnings and currently has the right factors in place that suggest it may exceed expectations in its upcoming quarterly report.
DGX's strong performance in its core business and the growing use of Advanced Diagnostics services are promising signs for the future.
Quest Diagnostics has launched Health Coaching on questhealth.com to assist people in managing their health better. This service aims to empower individuals to take charge of their well-being.
A new service helps people reach their health goals by combining Quest lab results with personalized coaching. Available for purchase on questhealth.com, this one-on-one health coaching is offered by Pack Health®, a Quest Diagnostics company. Individuals will work with certified health advisers who provide tailored support and resources based on their specific health objectives.
Quest Diagnostics (DGX) has received a Zacks Rank #2 (Buy) upgrade, indicating increased confidence in the company's potential earnings. This could lead to a rise in the stock price soon.
DGX shows strong performance in its core business. The growing use of the Advanced Diagnostics service is also a good sign.
SECAUCUS, N.J., Nov. 12, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a top company in diagnostic information services, has announced that its Board of Directors has approved a quarterly cash dividend of $0.75 per share. This dividend will be paid on January 29, 2025, to shareholders who own Quest Diagnostics common stock as of January 14, 2025.
Investors who focus on Medical - Outpatient and Home Healthcare stocks probably know about Quest Diagnostics (DGX) and The Pennant Group, Inc. (PNTG). However, which of these companies is the better choice for those seeking undervalued stocks?
Quest Diagnostics (DGX) has reached its highest point in the last year, but can investors expect further growth? We will examine the company's fundamentals for insights.
Quest Diagnostics is seeing more lab tests, especially in genetic testing, due to an older population, and it provides a 2.0% dividend yield. The company's strategy for mergers and acquisitions, like buying LifeLabs, is designed to grow its presence and diversify its services, even though it may temporarily lower earnings per share. While there are risks from reimbursement cuts and labor market issues, Quest Diagnostics anticipates long-term growth from both its own efforts and acquisitions.
FAQ
- What is the primary business of Quest Diagnostics Incorporated?
- What is the ticker symbol for Quest Diagnostics Incorporated?
- Does Quest Diagnostics Incorporated pay dividends?
- What sector is Quest Diagnostics Incorporated in?
- What industry is Quest Diagnostics Incorporated in?
- What country is Quest Diagnostics Incorporated based in?
- When did Quest Diagnostics Incorporated go public?
- Is Quest Diagnostics Incorporated in the S&P 500?
- Is Quest Diagnostics Incorporated in the NASDAQ 100?
- Is Quest Diagnostics Incorporated in the Dow Jones?
- When was Quest Diagnostics Incorporated's last earnings report?
- When does Quest Diagnostics Incorporated report earnings?
- Should I buy Quest Diagnostics Incorporated stock now?